Aspirin use Reduces Platelet Hyperreactivity and Degranulation in COVID-19 Patients

Abstract

Letter to the Editor 92This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part IV

“…The remainder of this issue contains several Commentaries as well as Letters to the Editor ("correspondence"). [19][20][21][22][23][24][25][26][27][28][29] Such material permits publication of various "smaller" COVID-19 vignettes. First comes a Commentary related to heparin anticoagulation in COVID-19 by Lippi et al 19 The authors discuss the benefits of heparin use from the perspectives of pleiotropic antiviral activity beyond anticoagulant and anti-inflammatory properties.…”

“…Next comes a series of Commentaries on the strength of anticoagulation in various categories of COVID-19 severity. [20][21][22] The final commentary in this issue of the journal is managing drugdrug interactions with oral anticoagulants and nirmatrelvir/ritonavir in COVID-19 outpatients by Rizk et al The remainder of the issue contains some correspondence (i.e., Letters to the Editor), [24][25][26][27][28][29] around the possibility of acquired thrombotic thrombocytopenic purpura (aTTP) after COVID-19 mRNA vaccination, aspirin use reducing platelet hyperreactivity and degranulation in COVID-19 patients, antiphospholipid syndrome in COVID-19, and molecular mimicry between human PF4 and SARS-CoV-2 spike protein as potential basis for autoimmune responses in vaccinated and naturally infected patients. For aTTP post-COVID-19 mRNA vaccination and antiphospholipid syndrome in COVID-19, the real questions are whether these events are caused by or coincidental to vaccination or COVID-19.…”

Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

“…Treatment of COVID-19 patients with aspirin, apixaban or P2Y12 inhibitors failed to yield a significant reduction in thromboembolic events in the multicentre RECOVERY trial [ 12 ] or the ACTIV4a trial [ 13 ]. Moreover, treatment of platelets of severe COVID-19 patients with aspirin failed to reduce platelet aggregation ex vivo [ 14 ]. In contrast, our results demonstrate an anticoagulant effect of ivacaftor ex vivo, especially in platelets from patients with severe COVID-19, suggesting a greater promise of this strategy to reduce the risk for thrombotic events in the clinical management of COVID-19 patients.…”